Compare · ABBV vs EVMN
ABBV vs EVMN
Side-by-side comparison of AbbVie Inc. (ABBV) and Evommune Inc. (EVMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and EVMN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $394.12B, about 542.0x EVMN ($727.2M).
- Over the past year, ABBV is up 19.2% and EVMN is up 3.7% - ABBV leads by 15.5 points.
- EVMN has been more active in the news (13 items in the past 4 weeks vs 10 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 10 for EVMN).
- Company
- AbbVie Inc.
- Evommune Inc.
- Price
- $225.38+1.06%
- $20.50+1.74%
- Market cap
- $394.12B
- $727.2M
- 1M return
- +11.93%
- -10.09%
- 1Y return
- +19.22%
- +3.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2025
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 10
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest EVMN
- SEC Form 4 filed by Director Mcgraw Benjamin F Iii
- SEC Form 4 filed by Director Kirsch Arthur S
- Director Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)
- Chief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)
- President & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)
- SEC Form 144 filed by Evommune Inc.
- SEC Form 424B3 filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)